Alzheimer's DiseasePhase 3MissionAD1NCT02956486
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
A Phase 3 study testing Elenbecestat in people with Alzheimer's Disease, run by Eisai Co., Ltd. at 258 sites in 18 countries.
Trial summary
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. Read more about this study
- Who is it for?
- Ages 50 to 85 years
- Conditions the study is for
- Alzheimer's Disease
- What is being tested?
- Elenbecestat
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 2,212 participants
- Where
- 258 sitesin 18 countries
- Study dates
- 20 Oct 2016to 15 Jan 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including
- Mini Mental State Examination score equal to or greater than 24
- Clinical Dementia Rating (CDR) global score of 0.5
- CDR Memory Box score of 0.5 or greater
- Impaired episodic memory confirmed by a list learning task
Show all 9Show fewer
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both
- Extension Phase
- Participants who complete the Core Study
Who cannot join
- Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
- Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)
Show all 26Show fewer
- Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years
- Have any contraindications to magnetic resonance imaging (MRI) scanning or
- Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
- Exhibit other significant pathological findings on brain MRI.
- Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)
- Results of laboratory tests conducted during Screening that are outside the following limits:
- Absolute lymphocyte count below the lower limit of normal (LLN)
- Thyroid stimulating hormone above normal range
- Abnormally low Vitamin B12 levels
- Participants at increased risk of infection
- Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
- Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
- Any other clinically significant abnormalities
- Severe visual or hearing impairment
- A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction [QTcF] greater than 450 milliseconds [ms])
- Malignant neoplasms within 5 years of Screening
- Known or suspected history of drug or alcohol abuse
- Taking prohibited medications, which must be reviewed with the Investigator
- Have participated in a recent clinical study
- Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.
Trial locations and contacts
258 sites in 18 countries.
258 sites in 18 countries
United States88 sites
Facility #1
Amherst, New York, 14226
Facility #1
Atlanta, Georgia, 30328
Facility #1
Atlantis, Florida, 33462
Facility #1
Austin, Texas, 78757
Facility #1
Aventura, Florida, 33187
Facility #2
Aventura, Florida, 33187
Facility #1
Bennington, Vermont, 5201
Facility #1
Boston, Massachusetts, 2115
Facility #1
Boynton Beach, Florida, 33437
Facility #1
Brooklyn, New York, 11229
Facility #1
Canton, Ohio, 44718
Facility #1
Centerville, Ohio, 45459
Facility #1
Chandler, Arizona, 85226
Facility #1
Chesterfield, Missouri, 63005
Facility #1
City of Saint Peters, Missouri, 63303
Facility #1
Cleveland, Ohio, 44195
Facility #1
Colton, California, 92324
Facility #1
Columbus, Georgia, 31909
Facility #1
Coral Gables, Florida, 33134
Facility #2
Coral Gables, Florida, 33134
Facility #1
Cordova, Tennessee, 38018
Facility #1
Costa Mesa, California, 92626
Facility #1
Dallas, Texas, 75231
Facility #1
Dayton, Ohio, 45459
Facility #1
Decatur, Georgia, 30033
Facility #1
Delray Beach, Florida, 33445
Facility #1
Denver, Colorado, 80218
Facility #1
Doral, Florida, 33122
Facility #1
East Providence, Rhode Island, 02914
Facility #1
Farmington Hills, Michigan, 48334
Facility #1
Fullerton, California, 92835
Facility #1
Hampton, Virginia, 23666
Facility #1
Hialeah, Florida, 33016
Facility #1
Houston, Texas, 77084
Facility #1
Imperial, California, 92251
Facility #1
Irvine, California, 92618
Facility #1
Jenkintown, Pennsylvania, 19046
Facility #1
Lakewood, Ohio, 44107
Facility #1
Lemon Grove, California, 91945
Facility #1
Madison, Wisconsin, 53705
Facility #1
Media, Pennsylvania, 19063
Facility #1
Meridian, Idaho, 83642
Facility #2
Miami, Florida, 33122
Facility #11
Miami, Florida, 33125
Facility #9
Miami, Florida, 33125
Facility #10
Miami, Florida, 33126
Facility #4
Miami, Florida, 33133
Facility #1
Miami, Florida, 33137
Facility #6
Miami, Florida, 33144
Facility #3
Miami, Florida, 33155
Facility #7
Miami, Florida, 33174
Facility #8
Miami, Florida, 33176
Facility #1
Mount Arlington, New Jersey, 7856
Facility #2
Nashville, Tennessee, 37203
Facility #1
Nashville, Tennessee, 37212
Facility #1
New York, New York, 10032
Facility #1
Northbrook, Illinois, 60062
Facility #1
O'Fallon, Missouri, 63368
Facility #1
Oceanside, California, 92054
Facility #2
Oceanside, California, 92054
Facility #1
Oklahoma City, Oklahoma, 73116
Facility #2
Orlando, Florida, 32801
Facility #1
Orlando, Florida, 32806
Facility #3
Orlando, Florida, 32807
Facility #1
Oxnard, California, 93030
Facility #1
Palm Beach Gardens, Florida, 33410
Facility #1
Panorama City, California, 91402
Facility #1
Philadelphia, Pennsylvania, 19104
Facility #1
Pompano Beach, Florida, 33064
Facility #1
Port Charlotte, Florida, 33952
Facility #1
Port Orange, Florida, 32127
Facility #1
Port Royal, South Carolina, 29935
Facility #1
Portland, Oregon, 97210
Facility #1
Providence, Rhode Island, 2906
Facility #1
Salt Lake City, Utah, 84108
Facility #1
San Antonio, Texas, 78229-3900
Facility #3
San Antonio, Texas, 78240
Facility #1
San Diego, California, 92123
Facility #1
Spring Hill, Florida, 34609
Facility #2
Springfield, New Jersey, 7081
Facility #2
St Louis, Missouri, 63104
Facility #1
Suwanee, Georgia, 30024
Facility #1
Tampa, Florida, 33613
Facility #2
Tampa, Florida, 33614
Facility #1
The Villages, Florida, 32162
Facility #1
West Long Branch, New Jersey, 7764
Facility #1
Westerville, Ohio, 43081
Facility #2
Wichita, Kansas, 67214
Japan48 sites
Eisai Trial Site 1
Anjo-shi, Aichi-ken, 446-8510
Eisai Trial Site 1
Bunkyo-ku, Tokyo, 113-0034
Eisai Trial Site 2
Bunkyo-ku, Tokyo, 113-8603
Eisai Trial Site 1
Fujioka-shi, Gunma, 375-0017
Eisai Trial Site 1
Fujisawa-shi, Kanagawa, 251-0038
Eisai Trial Site 1
Higashimorokatagun, Miyazaki, 880-1111
Eisai Trial Site 1
Himeji, Hyōgo, 671-1227
Eisai Trial Site 2
Himeji-shi, Hyōgo, 670-0981
Facility #1
Hiragi, Kagawa-ken, 761-0793
Eisai Trial Site 1
Hirakata, Osaka, 573-1121
Eisai Trial Site 1
Hofu-shi, Yamaguchi, 747-0802
Eisai Trial Site 1
Kanzaki-gun, Saga-ken, 842-0192
Eisai Trail Site 1
Kitakyushu-shi, Fukuoka, 808-0024
Eisai Trial Site 1
Kobe, Hyōgo, 650-0017
Eisai Trial Site 1
Kodaira-shi, Tokyo, 187-8551
Eisai Trial Site 1
Kumamoto, 860-8556
Eisai Trial Site 1
Kurashiki-shi, Okayama-ken, 710-0813
Eisai Trial Site 2
Kurashiki-shi, Okayama-ken, 710-8692
Eisai Trial Site 1
Kyoto, Kyoto, 602-8566
Eisai Trial Site 2
Kyoto, Kyoto, 602-8566
Eisai Trial site 5
Kyoto, Kyoto, 607-8113
Eisai Trial Site 4
Kyoto, Kyoto, 616-8255
Eisai Trial Site 3
Kyoto, 606-0851
Eisai Trial Site 1
Minato-ku, Tokyo, 108-0073
Eisai Trial Site 1
Nagoya, Aichi-ken, 467-8602
Eisai Trial Site 1
Naniwa-Ku, Osaka, 556-0017
Eisai Trial Site 1
Obu-shi, Aichi-ken, 474-8511
Eisai Trial Site 1
Okayama, Okayama-ken, 700-8557
Eisai Trial Site 2
Okayama, Okayama-ken, 701-1192
Eisai Trial Site 1
Omuta-shi, Fukuoka, 837-0911
Eisai Trial Site 1
Osaka, Osaka, 534-0021
Eisai Trial Site 3
Osaka, Osaka, 543-8555
Eisai Trial Site 2
Osaka, Osaka, 545-8586
Eisai Trial Site 1
Osaka, 553-0003
Eisai Trial Site 1
Otake-shi, Hiroshima, 739-0651
Eisai Trial Site 2
Ōtsu, Shiga, 520-0832
Eisai Trial Site 1
Ōtsu, Shiga, 520-2192
Eisai Trial site 2
Sakai-shi, Osaka, 593-8301
Eisai Trial Site 1
Setagaya-ku, Tokyo, 158-8531
Eisai Trial Site 1
Shimogyo-ku, Kyoto, 600-8558
Eisai Trial Site 1
Shinjuku-ku, Tokyo, 169-0073
Eisai Trial Site 1
Suita-shi, Osaka, 565-0871
Eisai Trial Site 2
Suita-shi, Osaka, 565-0874
Eisai Trial Site 1
Sumida-ku, Tokyo, 130-0004
Eisai Trial Site 1
Suminoe-ku, Osaka, 559-0004
Eisai Trial Site 3
Takamatsu, Kagawa-ken, 760-8557
Eisai Trial Site 1
Tokushima, Tokushima, 770-8503
Eisai Trial Site 1
Yoshida-gun, Fukui, 910-1193
United Kingdom24 sites
Facility #1
Aberdeen, Scotland, AB25 2ZH
Facility #1
Bath, North East Somerset, BA1 3NG
Facility #1
Birmingham, West Midlands, B168QQ
Facility #1
Blackpool, Lancashire, FY2 0JH
Facility #1
Bournemouth, Dorset, BH1 4JQ
Facility #1
Cambridge, Cambridgeshire, CB21 5EF
Facility #1
Chester, Cheshire, CH2 1BQ
Facility #1
Crowborough, East Sussex, TN6 1HB
Facility #1
Glasgow, Lanarkshire, G20 0XA
Facility #2
Glasgow, G51 4TF
Facility #1
Guildford, GU2 7YD
Facility #1
Leatherhead, Surrey, KT22 7AD
Facility #2
London, Middlesex, TW7 6FY
Facility #1
London, W1G 9RU
Facility #4
London, W6 8RF
Facility #3
London, WC1X 8QD
Facility #1
Manchester, Greater Manchester, M13 9WL
Facility #1
Oxford, Oxfordshire, OX3 7JX
Facility #1
Plymouth, Devon, PL6 8BT
Facility #1
Preston, Lancashire, PR2 8DW
Facility #1
Sheffield, South Yorkshire, S5 7JT
Facility #1
Southampton, Hampshire, SO30 3JB
Facility #1
Swindon, Wilts, SN3 6BW
Facility #1
Winwick, Warrington, Cheshire, WA2 8WA
Argentina14 sites
Facility #4
Buenos Aires, 1199
Facility #2
Caba, Buenos Aires, -1405
Facility #1
Caba, Buenos Aires, C1012AAR
Facility #4
Caba, Buenos Aires, C1126AAB
Facility #3
Caba, Buenos Aires, C1427
Facility #5
Caba, C1428AQK
Facility #1
Ciudad Autonoma de Buenos Aires, Buenos Aires, 1111
Facility #3
Ciudad Autonoma de Buenos Aires, Buenos Aires, 1430
Facility #2
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1230AAZ
Facility #1
Córdoba, Capital, X5003DCE
Facility #2
Córdoba, X5004A0A
Facility #3
Córdoba, X5009BIN
Facility #1
Rosario, Santa Fe Province, 2000
Facility #1
Santa Fe, 3000
Australia12 sites
Facility #1
Brisbane, Queensland, 4032
Facility #1
Caulfield, Victoria, 3162
Facility #1
Darlinghurst, New South Wales, 2010
Facility #1
Geelong, Victoria, 3220
Facility #1
Heidelberg, Victoria, 3084
Facility #1
Macquarie Park, New South Wales, 2113
Facility #1
Malvern, Victoria, 3144
Facility #2
Melbourne, Victoria
Facility #3
Melbourne, 3146
Facility #1
Nedlands, Western Australia, 6009
Facility #1
Parkville, Victoria, 3050
Facility #1
Tumbi Vmbi, New South Wales, 2261
Spain11 sites
Facility #1
Barcelona, 8028
Facility #1
Donostia / San Sebastian, Gipuzkoa, 20009
Facility #1
El Palmar, Murcia, 30120
Facility #1
Elche, Alicante, 3203
Facility #1
Getxo, Bizkaia, 48993
Facility #2
Madrid, 28049
Facility #1
Madrid, 28223
Facility #1
Palma de Mallorca, Balearic Islands, 7120
Facility #1
Sant Cugat del Vallès, Barcelona, 8195
Facility #1
Valencia, 46010
Facility #2
Valencia, 46026
Germany10 sites
Facility #1
Berlin, 10245
Facility #2
Berlin, 10629
Facility #1
Frankfurt am Main, Hesse, 60528
Facility #1
Gera, 7551
Facility #1
Homburg/Saar, 66241
Facility #1
Hoppegarten, Brandenburg, 15366
Facility #1
Leipzig, Saxony, 4107
Facility #1
Neuburg am Inn, Bavaria, 86633
Facility #1
Oranienburg, Brandenburg, 16515
Facility #1
Schwerin, 19053
South Korea10 sites
Facility #1
Bucheon-si, Gyeonggi-do, 14647
Facility #1
Busan, 49201
Facility #1
Incheon, 22332
Facility #1
Seongnam-si, Gyeonggi-do, 13620
Facility #5
Seoul, 3722
Facility #3
Seoul, 4763
Facility #1
Seoul, 5030
Facility #4
Seoul, 6351
Facility #6
Seoul, 6973
Facility #2
Seoul, 7985
Canada9 sites
Facility #1
Halifax, Nova Scotia, B3S 1M7
Facility #1
Kamloops, British Columbia, V2C 5T1
Facility #1
Kelowna, British Columbia, V1Y 1Z9
Facility #1
Kentville, Nova Scotia, B4N 4K9
Facility #1
Montreal, Quebec, H1M 1B1
Facility #1
Ottawa, Ontario, K1N 5C8
Facility #1
Peterborough, Ontario, K9H 2P4
Facility #1
Sherbrooke, Quebec, J1L 0H8
Facility #1
West Vancouver, British Columbia, V7T 1C5
France8 sites
Facility #1
Bordeaux, 33076
Facility #1
Bron, 69677
Facility #1
Marseille, 13385
Facility #1
Montpellier, Herault, 34295
Facility #1
Nantes, 44800
Facility #1
Paris, 75013
Facility #1
Rouen, 76000
Facility #1
Toulouse, 31059
Bulgaria7 sites
Facility #1
Pleven, 5800
Facility #1
Plovdiv, 4002
Facility #1
Rousse, 7002
Facility #4
Sofia, 1142
Facility #3
Sofia, 1309
Facility #1
Sofia, 1431
Facility #2
Sofia, 1431
Poland7 sites
Facility #1
Katowice
Facility #1
Kielce, 25-411
Facility #1
Krakow, 30-149
Facility #1
Poznan
Facility #1
Poznari, 61-853
Facility #1
Siemianowice Śląskie, 41-100
Facility #1
Warsaw, 01-684
Czechia4 sites
Facility #1
Hradec Králové, 500 09
Facility #1
Kladno, 272 01
Facility #1
Olomouc, 779 00
Facility #1
Prague, 109 00
About this study
Official title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
- Conditions
- Alzheimer's Disease
- Being tested
- Elenbecestat, Placebo
- Keywords
- Elenbecestat, E2609, Alzheimer's Disease, Early Alzheimer's Disease, Prodromal Alzheimer's Disease, Dementia, Dementia, Alzheimer's type, Mild Cognitive Impairment, MissionAD1
- Medical subject headings
- Alzheimer Disease, Dementia, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ElenbecestatDrug
Also called E2609
Oral tablet.
PlaceboDrug
Oral tablet.
| Study group | Role | What they receive |
|---|---|---|
| Core Study: Elenbecestat 50 mg | Experimental | Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded. Receives: Drug: Elenbecestat |
| Core Study: Placebo | Placebo comparator | Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded. Receives: Drug: Placebo |
| Open-label Extension Phase: Elenbecestat 50 mg | Experimental | Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning. Receives: Drug: Elenbecestat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score
The clinical dementia rating (CDR) scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
A TEAE is defined as an adverse event that emerged during treatment or within 28 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) were reported based on their safety assessments of laboratory tests, suicidal ideation and suicidal behavior, drug abuse potential, physical examination, neurological examination, regular measurement of vital signs, magnetic resonance imaging and electrocardiogram parameter values.
Measured: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase
Secondary outcomes (25)
Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)
ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog), the Mini Mental State Examination (MMSE), and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)
Amyloid PET scan assesses cerebral amyloid load using 3 tracers (florbetapir, florbetaben and flutemetamol) which is standardized into centiloids for evaluation of AD. Centiloid values on centiloid scale is based on mean composite SUVR in cingulate, frontal, parietal and temporal cortexes using whole cerebellum as reference region. SUVR is ratio of tracer uptake in each of cingulate, frontal, parietal and temporal cortexes relative to cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scans.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment. Amyloid PET scans allow in vivo assessment of cerebral amyloid load. SUVR indicates the ratio of tracer uptake in the frontal cortex relative to the cerebellum or the ratio of tracer uptake in the whole brain relative to the cerebellum.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance. Amyloid PET scans allow in vivo assessment of cerebral amyloid load. SUVR indicates the ratio of tracer uptake in the frontal cortex relative to the cerebellum or the ratio of tracer uptake in the whole brain relative to the cerebellum.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24
The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment. In this outcome measure, change per year (mean slope) in CDR-SB score was calculated up to month 24, where higher change indicated more impairment and lower change indicated less impairment.
Measured: Up to Month 24 of the core phase
Core Phase: Time to Worsening of CDR Score up to Month 24
The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The global CDR score is computed via an algorithm and ranges from 0 to 3. Higher score indicates more impairment. In this outcome measure, time (in months) to worsening of CDR score (that is, an increase from baseline by at least 0.5 points on the global CDR scale on 2 consecutive scheduled visits) up to month 24 was calculated.
Measured: Up to Month 24 of the core phase
Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24
Time (in months) to conversion to dementia for participants who were not clinically staged as having dementia at the core phase baseline (that is time from randomization to conversion to dementia in clinical diagnosis).
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score
ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0-10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The total score ranges from 0 to 90. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the MMSE Score
The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score was missing then the total score was missing. Higher score indicates better function.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score
FAQ scores 10 items \& measures activities of daily living (paying bills/balancing checkbook, assembling tax records, shopping alone for clothes or groceries, playing game of skill such as bridge or chess/working on a hobby, heating water \& turning off stove, preparing balanced meal, keeping track of current events, paying attention \& understanding television program, remembering appointments, driving or traveling out of neighborhood). Each item is rated as follows: 0=Normal, 1=Has difficulty but does by self, 2=Requires assistance, 3=Dependent, or 8=Not Applicable. The total score is the sum of all 10 items \& ranges from 0 to 30. Higher score indicates more impairment. If any activity was missed, then the total score was missed. Activities rated as "Not Applicable" were not used in the computation of the total score. To account for "Not Applicable" activity, the total score was weighted as:Total Score=Total Score*30/(30 minus 3 times the number of activities marked"Not Applicable").
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score
ADAS-cog11 is a psychometric instrument that evaluates 11-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5] test) and is considered more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total score ranges from 0 to 70. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Last Dose in the CDR-SB Score
The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow up (up to Month 27)
Core Phase: Change From Last Dose in the ADCOMS
ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog11 Score
ADAS-cog11 is a psychometric instrument that evaluates 11-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5] test) and is considered more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total score ranges from 0 to 70. Higher score indicates more impairment.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog14 Score
ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The Total Score ranges from 0 to 90. Higher score indicates more impairment.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the MMSE Score
The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score was missing then the total score was missing. Higher score indicates better function.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.
Measured: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score
The CDR scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS
ADCOMS is a weighted linear combination of 12 items from three existing clinical scales: the ADAS-cog, the MMSE, and the CDR. Four items are from the ADAS-cog (A4 [Delayed Word Recall], A7 [Orientation], A8 [Word Recognition], A11 [Word Finding]); 2 items are from the MMSE (M1 [Orientation Time], M7 [Drawing]); 6 items are from the CDR (C1 [Personal Care], C2 [Community Affairs], C3 [Home and Hobbies], C4 [Judgment and Problem Solving], C5 [Memory], C6 [Orientation]). Composite score is derived from the variables from the 12 items, and ranges from 0 to 1.97, where higher score indicates worse performance.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score
The MMSE is a cognitive instrument commonly used for screening purposes, for staging of disease severity and is often measured longitudinally in AD clinical studies to follow disease progression and treatment effects. MMSE is composed of 30 questions grouped into domains (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Naming [0-2], Repetition [0-1], Comprehension [0-3], Reading [0-1], Writing [0-1], Drawing [0-1]). For each of the MMSE domains, six items are computed (Orientation to Time [0-5], Orientation to Place [0-5], Registration [0-3], Attention and Calculation [0-5], Recall [0-3], Language: Naming, Repetition, Comprehension, Reading, Writing, and Drawing [0-9]). The MMSE Total Score is the sum of the six domains and ranges from 0 to 30. If any domain score is missing then the total score is missing. Higher score indicates better function.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score
FAQ scores 10 items \& measures activities of daily living (paying bills/balancing checkbook, assembling tax records, shopping alone for clothes or groceries, playing game of skill such as bridge or chess/working on a hobby, heating water \& turning off stove, preparing balanced meal, keeping track of current events, paying attention \& understanding television program, remembering appointments, driving or traveling out of neighborhood). Each item is rated as follows: 0=Normal, 1=Has difficulty but does by self, 2=Requires assistance, 3=Dependent, or 8=Not Applicable. The total score is the sum of all 10 items \& ranges from 0 to 30. Higher score indicates more impairment. If any activity was missed, then the total score was missed. Activities rated as "Not Applicable" were not used in the computation of the total score. To account for "Not Applicable" activity, the total score was weighted as:Total Score=Total Score*30/(30 minus 3 times the number of activities marked"Not Applicable").
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score
ADAS-cog14 is a psychometric instrument that evaluates 14-items (Immediate Word-recall [0 to 10], Commands [0-5], Constructional Praxis [0-5], Delayed Word-recall [0-10], Naming Objects/Fingers [0-5], Ideational Praxis [0-5], Orientation[0-8], Word Recognition [0-12], Remembering Test Instructions [0-5], Comprehension[0-5], Word Finding Difficulty [0-5], Spoken Language Ability [0-5], Executive Function [0-5], and Number Cancellation [0-5] test). It is considered to be more sensitive for less impaired populations such as MCI/Prodromal and mild AD participants. The total score ranges from 0 to 90. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
The ADAS-cog14 Word List is a summation of two items: "Immediate Word-recall" and "Delayed Word-recall". Immediate Word-recall test: Participants are asked to recall words and the number of "No" responses for each trial (total 3 trials) are summed. Subscore: sum of scores from 3 trials, divided by 3. Score ranges from 0 to 10. Delayed Word-recall: Participants used to recall words after a delay and the number of "No" responses are summed. Score ranges from 0 to 10. The Total Score ranges from 0 to 20. Higher score indicates more impairment.
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase
Time (in months) to conversion to dementia for participants who were not clinically staged as having dementia at the core phase baseline (that is time from randomization to conversion to dementia in clinical diagnosis).
Measured: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2016 (estimated)
- Study start20 Oct 2016
- Primary completion15 Jan 2020
- Study completion15 Jan 2020
Why it stopped: Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 2,212 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eisai Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Biogen
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02956486
- Sponsor's protocol ID
- E2609-G000-301
- Other IDs
- 2016-003928-23, 2016-004128-42, 2016
- Acronym
- MissionAD1
- Status last verified
- Jan 2021
- First submitted
- 3 Nov 2016
- Last updated
- 3 Feb 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, Llano DA, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 2024 Aug;20(8):5617-5628. doi: 10.1002/alz.14073. Epub 2024 Jun 28.
PubMed 38940656Devanarayan V, Ye Y, Charil A, Andreozzi E, Sachdev P, Llano DA, Tian L, Zhu L, Hampel H, Kramer L, Dhadda S, Irizarry M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimers Dement. 2024 Mar;20(3):1725-1738. doi: 10.1002/alz.13565. Epub 2023 Dec 13.
PubMed 38087949Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roe-Vellve N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.
PubMed 35897078
Study at a glance
From the registry record, last updated by the sponsor on 3 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT02956486
- Acronym / sponsor ID
- MissionAD1 / E2609-G000-301
- Conditions
- Alzheimer's Disease
- Keywords
- Elenbecestat, E2609, Alzheimer's Disease, Early Alzheimer's Disease, Prodromal Alzheimer's Disease, Dementia, Dementia, Alzheimer's type, Mild Cognitive Impairment
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.
- Enrolment
- 2,212 participants (actual)
- Lead sponsor
- Eisai Co., Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Biogen
- Study start
- 20 Oct 2016 (actual)
- Primary completion
- 15 Jan 2020 (actual)
- Study completion
- 15 Jan 2020 (actual)
- First posted
- 7 Nov 2016 (estimated)
- Results
- Posted 3 Feb 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Core Study: Elenbecestat 50 mg | Experimental | Drug: ElenbecestatParticipants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded. |
| Core Study: Placebo | Placebo comparator | Drug: PlaceboParticipants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded. |
| Open-label Extension Phase: Elenbecestat 50 mg | Experimental | Drug: ElenbecestatParticipants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning. |
Who may qualify
- Ages
- 50 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Core Study
- Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including
- Impaired episodic memory confirmed by a list learning task
- Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both
- Extension Phase
Key exclusion criteria (26 listed)
- Core Study
- Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
- Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
- Participants with a history of seizures within 5 years of Screening
- History of transient ischemic attacks or stroke within 12 months of Screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ElenbecestatAlso: E2609Oral tablet. | Drug | Core Study: Elenbecestat 50 mg, Open-label Extension Phase: Elenbecestat 50 mg |
| PlaceboOral tablet. | Drug | Core Study: Placebo |
Primary outcome
Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
The clinical dementia rating (CDR) scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.
Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
Time frame: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase
A TEAE is defined as an adverse event that emerged during treatment or within 28 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) were reported based on their safety assessments of laboratory tests, suicidal ideation and suicidal behavior, drug abuse potential, physical examination, neurological examination, regular measurement of vital signs, magnetic resonance imaging and electrocardiogram parameter values.
25 secondary outcomes
Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24
Time frame: Up to Month 24 of the core phase
Core Phase: Time to Worsening of CDR Score up to Month 24
Time frame: Up to Month 24 of the core phase
Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the MMSE Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Core Phase: Change From Last Dose in the CDR-SB Score
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow up (up to Month 27)
Core Phase: Change From Last Dose in the ADCOMS
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog11 Score
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog14 Score
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the MMSE Score
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
Time frame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase
Time frame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Feb 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38940656Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, Llano DA, Zhou J, Reyderman L, Hampel H, Kramer LD, Dhadda S, Irizarry MC. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimers Dement. 2024 Aug;20(8):5617-5628. doi: 10.1002/alz.14073. Epub 2024 Jun 28.
- Derived from this study: PubMed 38087949Devanarayan V, Ye Y, Charil A, Andreozzi E, Sachdev P, Llano DA, Tian L, Zhu L, Hampel H, Kramer L, Dhadda S, Irizarry M; Alzheimer's Disease Neuroimaging Initiative (ADNI). Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimers Dement. 2024 Mar;20(3):1725-1738. doi: 10.1002/alz.13565. Epub 2023 Dec 13.
- Derived from this study: PubMed 35897078Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roe-Vellve N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.
- Individual participant dataSharing planned: Undecided
Related trials for Alzheimer's Disease
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Enrolling by invitationPhase 2
Tau PET Outcomes With Anti-amyloid Immunotherapies
Cognitive Impairment, Mild, Dementia, Mild
Active, not recruiting
Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial
Dementia, Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
258 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Elenbecestat in people with Alzheimer's Disease, run by Eisai Co., Ltd. at 258 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 3 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 258 sites in United States, Japan, United Kingdom, Argentina, Australia and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score (time frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02956486, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Feb 2021.